Dimethyl Fumarate

BOSTON — Relapse rates for patients with MS who took dimethyl fumarate were consistently low over the course of 5 years, Krupa Shah Pandey, MD, said in this Healio video.

BOSTON — Women with MS who were exposed to dimethyl fumarate in the first trimester had no unexpected adverse pregnancy outcomes, according to Kerstin Hellwig, MD, in this Healio video from the American Academy of Neurology annual meeting.

In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more.

Results from the EVOLVE-MS-1 study show Vumerity was effective and well-tolerated over 96 weeks in patients with relapsing-remitting MS compared with dimethyl fumarate, according to a presentation at ECTRIMS 2022.

Dimethyl fumarate was safe and lowered relapse rates for up to 5 years in Black and Hispanic/Latino patients with relapsing-remitting multiple sclerosis, according to a poster at the Consortium of Multiple Sclerosis Centers annual meeting.

Dimethyl fumarate and fingolimod appeared to have no significant difference in relapse rates, and rituximab appeared to have better relapse outcomes than natalizumab in patients with MS, according to results published in JAMA Network Open.